Key result
Antiplatelet monotherapy for secondary prevention after ischemic stroke and transient ischemic attacks is reviewed to assess its continued clinical viability.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
International audience
No takes yet. Share an insight, caveat, or question.
Diener et al. (2011) studied this question. Antiplatelet monotherapy for secondary prevention after ischemic stroke and transient ischemic attacks is reviewed to assess its continued clinical viability.
Synapse has enriched 10 related papers. Consider them for comparative context: